H.C. Wainwright Remains Bullish on Century Therapeutics (IPSC)

Century Therapeutics, Inc. (NASDAQ:IPSC) is one of the best performing small cap stocks so far in 2026. H.C. Wainwright lifted the price target on Century Therapeutics, Inc. (NASDAQ:IPSC) to $5 from $2 on April 21, maintaining a Buy rating on the shares. The firm told investors in a research note that Vertex has shown stem-cell islets can work and Sana has shown hypoimmune-edited islets can survive, adding that Century Therapeutics, Inc. (NASDAQ:IPSC) is attempting to combine these two proof points in CNTY-813. It added CNTY-813 into its model, with a 20% probability of approval and peak sales of $3.4 billion across the globe.

For additional reference, in its full year 2025 results, Century Therapeutics, Inc. (NASDAQ:IPSC) reported that its cash, cash equivalents, and marketable securities are $117.1 million as of December 31, 2025, as compared to $220.1 million as of December 31, 2024. In addition, collaboration revenue generated by the company’s collaboration, option, and license agreement with Bristol-Myers Squibb was $109.2 million for the year ended December 31, 2025, compared to $6.6 million for the prior year period.

Century Therapeutics, Inc. (NASDAQ:IPSC) develops off-the-shelf cell therapies to advance the course of cancer care, with a focus on harnessing the power of adult stem cells to develop curative allogeneic cell therapies for cancer.

While we acknowledge the risk and potential of IPSC as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than IPSC and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.